| Description | Girentuximab (G250) is a potent anti-carbonic anhydrase IX (CAIX) monoclonal antibody with anticancer activity for the study of uroepithelial carcinoma PET (ZiPUP). |
| In vitro | Girentuximab是一种嵌合鼠源单克隆抗体（mAb），具有IgG1 κ轻链，能识别CAIX抗原[1]。 |
| Synonyms | cG250, WX-G250, G250 |
| molecular weight | N/A |
| CAS | 916138-87-9 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Chamie K, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017;3(7):913-920. |